Ken Griffin Assembly Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$0.65 - $1.25 $4,940 - $9,500
-7,600 Reduced 71.7%
3,000 $2,000
Q3 2023

Nov 14, 2023
SELL
$0.87 - $1.13 $4,002 - $5,197
-4,600 Reduced 30.26%
10,600 $9,000
Q2 2023

Aug 14, 2023
SELL
$0.81 - $1.15 $9,639 - $13,684
-11,900 Reduced 43.91%
15,200 $17,000
Q1 2023

May 15, 2023
BUY
$0.8 - $1.74 $7,360 - $16,008
9,200 Added 51.4%
27,100 $22,000
Q4 2022

Feb 14, 2023
BUY
$1.09 - $20.4 $19,511 - $365,160
17,900 New
17,900 $23,000

Others Institutions Holding ASMB

# of Institutions
1
Shares Held
16.3K
Call Options Held
0
Put Options Held
0
View Full List

About ASSEMBLY BIOSCIENCES, INC.

ASMB Quotes by TradingView
  • Ticker ASMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,436,900
  • Market Cap $765M
  • Description
  • Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...
More about ASMB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email